Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

161. Lacosamide - Epilepsy

-onset seizures with or without secondary generalisation in adult and adolescent (16-18 years) patients with epilepsy. The legal basis for this application refers to: Generic application (Article 10(1) of Directive No 2001/83/EC) The application submitted is composed of administrative information, complete quality data and literature from the reference medicinal product Vimpat instead of non-clinical and clinical unless justified otherwise. The chosen reference product is: Medicinal product which (...) membranes. Vimpat was first approved as an adjunctive therapy for the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older. An extension of indication from add-on treatment to monotherapy was approved on 10 November 2016. At the time of this report, Vimpat was indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent (16-18 years

2017 European Medicines Agency - EPARs

162. A SYSTEMATIC REVIEW ON MONITORING OF PRESCRIPTION PATTERN AND QUALITY OF LIFE AMONG THE PATIENTS WITH EPILEPSY Full Text available with Trip Pro

factors affecting anti-epileptic drug (AED) usage; the main factors are the type of epilepsy, age and gender of patient and availability of medicines and affordability of the patient, and preference of the treating physician. To control epilepsy, the treatment attempt is done by using mono and polytherapy. To analyze commonly prescribed drugs as newer or old AEDs. 50% to 70% of patients can be treated with one antiepileptic drug (AED) as monotherapy, but all are not seizure free. So patients (...) OF LIFE AMONG THE PATIENTS WITH EPILEPSY Thasni K.*, Shamna Sadan and Dr. Abdurahiman ABSTRACT Prescription pattern monitoring studies (PPMS) and Quality of life (QOL) in epileptic patients is the tool for assessing the prescribing, dispensing and distribution of medicines and their effect on quality of life. The main aim of the review is to discuss the topic of the prescription pattern and quality of life in patients with epilepsy. From the prescription pattern study, we can assess the various

2017 World Journal of Pharmaceutical Research

163. Clinical features of seizures after cerebral venous sinus thrombosis and its effect on outcome among Chinese Han population Full Text available with Trip Pro

Clinical features of seizures after cerebral venous sinus thrombosis and its effect on outcome among Chinese Han population Clinical features of epileptic seizures after cerebral venous sinus thrombosis (CVST) among Chinese patients are not known, and it is still controversial whether seizures would affect the outcome of CVST.In a Chinese hospital-based study of consecutive patients with CVST between 2003 and 2015, we described the clinical features of seizures and determined the predictors (...) of seizure onset using multivariable logistic regression analysis. We also compared the in-hospital case-fatality and short-term functional outcome (modified Rankin Scale (mRS) at discharge) in patients with versus without seizures using ordinal regression analysis.Among 151 patients with CVST, 52 (34.4%) presented seizures, of which 42 (80.8%) were generalised seizures. Male gender (OR 6.32, 95% CI 2.06 to 19.35, p=0.001), motor deficits (OR 4.89, 95% CI 1.52 to 15.68, p=0.008), intracerebral

2017 Stroke and vascular neurology

164. Epilepsy as a health problem among school children in Turaif, Northern Saudi Arabia, 2017 Full Text available with Trip Pro

Epilepsy as a health problem among school children in Turaif, Northern Saudi Arabia, 2017 Epilepsy is the most common serious neurological disorder and is one of the world's most prevalent non-communicable diseases. There are no recently published data on the prevalence of epilepsy in school children in Northern Saudi Arabia.This study was conducted to determine the prevalence of epilepsy and to show some of its risk factors in school children and adolescents (6-18 years) in Turaif city (...) test and descriptive statistics.Out of 1,230 children, 66 (5.5%) had epilepsy; 68.2% of them were males and 31.8% females (p=0.000). Consanguinity between parents plays a significant role where 59.1% of cases had parents who were cousins (p=0.000). Family history also had a significant effect as 68.2% of cases had epilepsy cases in their families (p=0.000).Epilepsy prevalence among school children (6-18 years) in Turaif city is higher in males than females. Consanguinity and positive family history

2017 Electronic physician

165. CRACKCast E102 – Seizures

, autonomic, and/or cognitive function.” Convulsion : “refers specifically to the motor manifestations of a seizure” ictal Period : “is the time during which a seizure or seizure-like activity occurs.” Post-ictal period : “A postictal period is an interval of altered mental status immediately following a seizure, generally lasting less than 1 hour.” Epilepsy : “Epilepsy refers to a condition of recurrent unprovoked seizures.” Seizures can be partial (focal) or generalized Partial seizure : “involve (...) will show epileptiform discharges REFRACTORY STATUS EPILEPTICUS = a seizure that does not terminate after treatment with a benzo plus second antiepileptic drug. [2] List 10 Causes of status epilepticus See Box 92.1 in Rosens 9 th Edition Broken down by: Metabolic Infectious Withdrawal syndromes CNS lesions Intoxication [3] List the differential diagnosis of ALOC post seizure See Box 92.2 – Differential Diagnosis of AMS in Patient Who Has Seized Post-ictal Period NCSE or subtle convulsive status

2017 CandiEM

166. Giant Epidermoid Cyst: A Rare Cause of Temporal Lobe Epilepsy Full Text available with Trip Pro

surgical strategy in individuals with ECs and seizures is not established. The evaluation of the cause and risk-benefit must be held to choose the appropriate surgical strategy: lesionectomy, lobectomy, or amygdalohippocampectomy. In this case, a lesionectomy was performed due to an absence of evidence of involvement of hippocampus and amygdala. Conclusion  Epilepsy secondary to ECs is a rare association. Lesionectomy can be an option with good results without increasing the morbidity. (...) Giant Epidermoid Cyst: A Rare Cause of Temporal Lobe Epilepsy Introduction  Epidermoid tumors represent approximately 0.3 to 1.8% of all intracranial brain tumors. Only 1.5% of all intracranial epidermoid cysts (ECs) invade the brain and secondary epilepsy is extremely rare. Since August 2014, a 59-year-old male smoker had been presenting bad smell feelings, totaling four episodes with sudden onset and duration of 2 minutes. On September 2014, after a sense of smell episode, it evolved

2017 Journal of neurological surgery reports

167. Models and detection of spontaneous recurrent seizures in laboratory rodents Full Text available with Trip Pro

Models and detection of spontaneous recurrent seizures in laboratory rodents Epilepsy, characterized by spontaneous recurrent seizures (SRS), is a serious and common neurological disorder afflicting an estimated 1% of the population worldwide. Animal experiments, especially those utilizing small laboratory rodents, remain essential to understanding the fundamental mechanisms underlying epilepsy and to prevent, diagnose, and treat this disease. While much attention has been focused (...) on epileptogenesis in animal models of epilepsy, there is little discussion on SRS, the hallmark of epilepsy. This is in part due to the technical difficulties of rigorous SRS detection. In this review, we comprehensively summarize both genetic and acquired models of SRS and discuss the methodology used to monitor and detect SRS in mice and rats.

2017 Zoological research

168. Felbamate as an add-on therapy for refractory partial epilepsy. Full Text available with Trip Pro

Felbamate as an add-on therapy for refractory partial epilepsy. This review is an update of a previously published review in the Cochrane Database of Systematic Reviews (Issue 7, 2014) on 'Felbamate as an add-on therapy for refractory epilepsy'. Epilepsy is a chronic and disabling neurologic disorder, affecting approximately 1% of the population. Up to 30% of people with epilepsy have seizures that are resistant to currently available drugs. Felbamate is one of the second-generation (...) antiepileptic drugs and we have assessed its effects as an add-on therapy to standard drugs in this review.To evaluate the efficacy and tolerability of felbamate versus placebo when used as an add-on treatment for people with refractory partial-onset epilepsy.For the latest update we searched the Cochrane Epilepsy Specialized Register, CENTRAL, MEDLINE, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform, up to 20 October 2016. There were no language and time restrictions. We

2017 Cochrane

169. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids with seizures and central pyrexia, in a patient requiring tracheal intubation and mechanical ventilation: A case report Full Text available with Trip Pro

Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids with seizures and central pyrexia, in a patient requiring tracheal intubation and mechanical ventilation: A case report Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) has been described in multiple case reports since it was first described in the literature in 2010. The patient described is a 54-year-old man with no significant medical history (...) who presented with ataxia, diplopia and hearing and taste disturbances. His GCS reduced to the point at which he required intubation and he was treated for 50 days on an intensive care unit. The patient's course also includes seizures, first described in 2014, and central pyrexia, which has not been previously described in case reports of CLIPPERS. Intravenous methylprednisolone resulted in a rapid and significant recovery; neurological rehabilitation is ongoing 10 months from diagnosis

2017 Journal of the Intensive Care Society

170. Intravenous immunoglobulins for epilepsy. Full Text available with Trip Pro

for epilepsy management. This is an updated version of the original Cochrane review published in Issue 1, 2011.To examine the effects of IVIg on the frequency and duration of seizures, quality of life and adverse effects when used as monotherapy or as add-on treatment for people with epilepsy.For the latest update, we searched the Cochrane Epilepsy Group Specialized Register (2 February 2017), the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (2 (...) and extracted data. We contacted study authors for additional information. Outcomes included percentage of people rendered seizure-free, 50% or greater reduction in seizure frequency, adverse effects, treatment withdrawal and quality of life.We included one study (61 participants). The included study was a randomized, double-blind, placebo-controlled, multi-centre trial which compared the treatment efficacy of IVIg as an add-on with a placebo add-on in patients with refractory epilepsy

2017 Cochrane

171. [Stiripentol for the treatment of severe myoclonic epilepsy in infants (dravet's syndrome)]

There is low quality evidence from two small randomized clinical trials suggesting that stiripentol might reduce the rate of seizures in severe myoclonic epilepsy in infants (Dravet's syndrome). There is no evidence showing improvement in cognitive impairment or quality of life in this group of patients at long term. This is a drug classified as "orphan drug", only approved in some European countries and Canada as adjuvant therapy in combination with clobazam and valproic acid for refractory generalized (...) tonic-clonic seizures in patients with severe myoclonic epilepsy in infants (Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproic acid. The clinical practice guidelines and the health sponsors from Europe and Canada suggest adding stiripentol for patients with Dravet's syndrome whose treatment with valproic acid, clobazam or topiramate has not been successful. Final publication URL www.iecs.org.ar Indexing Status Subject indexing assigned by CRD MeSH Dioxolanes

2017 Health Technology Assessment (HTA) Database.

172. [Invasive electroencephalography monitoring with depth electrodes in presurgical assessment of patients with refractory epilepsy]

[Invasive electroencephalography monitoring with depth electrodes in presurgical assessment of patients with refractory epilepsy] [Invasive electroencephalography monitoring with depth electrodes in presurgical assessment of patients with refractory epilepsy] [Invasive electroencephalography monitoring with depth electrodes in presurgical assessment of patients with refractory epilepsy] Soto N, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Soto N, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A. [Invasive electroencephalography monitoring with depth electrodes in presurgical assessment of patients with refractory epilepsy] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de

2017 Health Technology Assessment (HTA) Database.

173. Should Antiepileptic Drugs Be Initiated in the Emergency Department After a First-Time Seizure? Full Text available with Trip Pro

. et al. Evidence-based guideline: management of an unprovoked first seizure in adults: report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology . 2015 ; 84 : 1705–1713 | | | | 3 Hauser, W.A. and Beghi, E. First seizure definitions and worldwide incidence and mortality. Epilepsia . 2008 ; 49 : 8–12 | | | | 4 Berg, A.T. and Shinnar, S. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review (...) assessment tool. Immediate antiepileptic drug treatment was associated with a reduced risk of seizure recurrence at 1 and 5 years after study enrollment ( Table ). However, another metric for assessing long-term outcome and prognosis is the seizure remission rate, x 2 Krumholz, A., Wiebe, S., Gronseth, G.S. et al. Evidence-based guideline: management of an unprovoked first seizure in adults: report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy

2017 Annals of Emergency Medicine Systematic Review Snapshots

174. Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Full Text available with Trip Pro

is the occurrence of generalized tonic-clonic seizures (GTCS); the SUDEP risk increases in association with increasing frequency of GTCS occurrence (high confidence in evidence).Level B: Clinicians caring for young children with epilepsy should inform parents/guardians that in 1 year, SUDEP typically affects 1 in 4,500 children; therefore, 4,499 of 4,500 children will not be affected. Clinicians should inform adult patients with epilepsy that SUDEP typically affects 1 in 1,000 adults with epilepsy per year (...) ; therefore, annually 999 of 1,000 adults will not be affected. For persons with epilepsy who continue to experience GTCS, clinicians should continue to actively manage epilepsy therapies to reduce seizures and SUDEP risk while incorporating patient preferences and weighing the risks and benefits of any new approach. Clinicians should inform persons with epilepsy that seizure freedom, particularly freedom from GTCS, is strongly associated with decreased SUDEP risk.© 2017 American Academy of Neurology.

2017 EvidenceUpdates

175. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. Full Text available with Trip Pro

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. The Dravet syndrome is a complex childhood epilepsy disorder that is associated with drug-resistant seizures and a high mortality rate. We studied cannabidiol for the treatment of drug-resistant seizures in the Dravet syndrome.In this double-blind, placebo-controlled trial, we randomly assigned 120 children and young adults with the Dravet syndrome and drug-resistant seizures to receive either cannabidiol oral solution (...) in the cannabidiol group.Among patients with the Dravet syndrome, cannabidiol resulted in a greater reduction in convulsive-seizure frequency than placebo and was associated with higher rates of adverse events. (Funded by GW Pharmaceuticals; ClinicalTrials.gov number, NCT02091375 .).

2017 NEJM Controlled trial quality: predicted high

176. Anticonvulsant effect of liraglutide, GLP-1 agonist by averting a change in GABA and brain glutathione level on picrotoxin-induced seizures Full Text available with Trip Pro

Anticonvulsant effect of liraglutide, GLP-1 agonist by averting a change in GABA and brain glutathione level on picrotoxin-induced seizures 28827991 2018 11 13 1611-2156 16 2017 EXCLI journal EXCLI J Anticonvulsant effect of liraglutide, GLP-1 agonist by averting a change in GABA and brain glutathione level on picrotoxin-induced seizures. 752-754 10.17179/excli2017-283 Gupta Gaurav G School of Pharmacy, Jaipur National University, Jagatpura 302017, Jaipur, India. School of Medicine and Public

2017 EXCLI journal

177. Topiramate monotherapy for juvenile myoclonic epilepsy. Full Text available with Trip Pro

Topiramate monotherapy for juvenile myoclonic epilepsy. Topiramate is a newer broad-spectrum antiepileptic drug (AED). Some studies have shown the benefits of topiramate monotherapy in the treatment of juvenile myoclonic epilepsy (JME). However, there are no current systematic reviews to determine the efficacy and tolerability of topiramate monotherapy in people with JME. This is an updated version of the original Cochrane Review published in Issue 12, 2015.To evaluate the efficacy (...) and tolerability of topiramate monotherapy in the treatment of JME.For the latest update, on 21 February 2017 we searched Cochrane Epilepsy's Specialized Register, CENTRAL, MEDLINE, and ClinicalTrials.gov. We also searched ongoing trials registers, reference lists and relevant conference proceedings, and contacted study authors and pharmaceutical companies.We included randomized controlled trials (RCTs) investigating topiramate monotherapy versus placebo or other AED treatment for people with JME

2017 Cochrane

178. Seroepidemiological study of Toxoplasma gondii infection in a population of Iranian epileptic patients Full Text available with Trip Pro

Seroepidemiological study of Toxoplasma gondii infection in a population of Iranian epileptic patients Epilepsy is one of the most common neurologic disorders. Underlying cause of epilepsy is unknown in 60 % of the patients. Toxoplasma gondii is an intracellular parasite which is capable of forming tissue cysts in brain of chronically infected hosts including humans. Some epidemiological studies suggested an association between toxoplasmosis and acquisition of epilepsy. In this study we (...) determined seroprevalence of latent Toxoplasma infection in a population of Iranian epileptic patients. Participants were classified in three groups as Iranian epileptic patients (IEP, n = 414), non-epileptic patients who had other neurologic disorders (NEP, n = 150), and healthy people without any neurologic disorders (HP, n = 63). The presence of anti-Toxoplasma IgG antibodies and IgG titer in the sera were determined by ELISA method. Anti-T. gondii IgG seroprevalence obtained 35.3 %, 34.7 % and 38.1

2017 EXCLI journal

179. Pregabalin Zentiva k.s. - neuropathic pain, epilepsy, generalised anxiety disorder

Zentiva k.s. is indicated for the treatment of peripheral and central neuropathic pain in adults. Epilepsy Pregabalin Zentiva k.s. is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. Generalised anxiety disorder Pregabalin Zentiva k.s. is indicated for the treatment of generalised anxiety disorder (GAD) in adults. The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions: Assessment report EMA (...) Pregabalin Zentiva k.s. - neuropathic pain, epilepsy, generalised anxiety disorder 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 15 December 2016 EMA/14344/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment

2017 European Medicines Agency - EPARs

180. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Full Text available with Trip Pro

Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. This is an updated version of the original Cochrane review originally published in 2003, Issue 3, and updated in 2005, Issue 4.Absence seizures are brief epileptic seizures which present in childhood and adolescence. Depending on clinical features and electroencephalogram (EEG) findings they are divided into typical, atypical absences, and absences with special features. Typical absences (...) valproate in children with newly diagnosed childhood absence epilepsy found that at 12 months, the freedom-from-failure rates for ethosuximide and valproic acid (VPA) were similar and were higher than the rate for lamotrigine. The frequency of treatment failures due to lack of seizure control (P < 0.001) and intolerable adverse events (P < 0.037) was significantly different among the treatment groups, with the largest proportion of lack of seizure control in the lamotrigine cohort, and the largest

2017 Cochrane